Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.60 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.60 |
| ▸ | CETP | P11597 | 1/20 | 0.54 |
| ▸ | GJB2 | P29033 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | IGF2R | P11717 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2443026 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL2443027 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL4106706 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL2448130 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL25480871 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL2447144 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL23016771 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL22691938 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL22111992 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL21067398 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018204669-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2018-11-08 | — | — | WO | claimed |
| EP-2278997-A1 | NANOEMULSION INFLUENZA VACCINE | Nanobio Corporation (US) | 2011-02-02 | — | — | EP | claimed |
| US-20100172845-A1 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIAL INFECTIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-07-08 | — | — | US | claimed |
| WO-2009131995-A1 | NANOEMULSION INFLUENZA VACCINE | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| US-20080269163-A1 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis | UNIVERSITY OF FUKUI (JP) | 2008-10-30 | — | — | US | claimed |
| EP-1814559-A1 | METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006045050-A1 | METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) | 2006-04-27 | — | — | WO | claimed |
| EP-0908172-A1 | Cosmetic and dermatological photoprotective compositions in the form of O/W emulsions containing hydrophobic inorganic micropigments and hydrophilic surfactants | Beiersdorf Aktiengesellschaft (DE) | 1999-04-14 | — | — | EP | claimed |
| EP-2259768-B1 | COMPOSITIONS CONTAINING CYCLIC PEPTIDES AND METHODS OF USE | MERCK PATENT GMBH (DE) | 2019-05-22 | — | — | EP | disclosed |
| US-10278911-B2 | Compositions containing cyclic peptides and methods of use | MERCK PATENT GMBH (DE) | 2019-05-07 | — | — | US | disclosed |
| EP-2553026-B1 | METAL OXIDE PARTICLES AFTER-TREATED WITH ORGANIC PHOSPHORUS COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-03-28 | — | — | EP | disclosed |
| EP-3218479-A1 | METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS | Nanocore ApS (DK) | 2017-09-20 | — | — | EP | disclosed |
| US-9700501-B2 | Use of indole compounds as a cosmetic | MERCK PATENT GMBH (DE) | 2017-07-11 | — | — | US | disclosed |
| US-20170105910-A1 | UV FILTER CAPSULE | BASF SE (DE) | 2017-04-20 | — | — | US | disclosed |
| EP-1250331-A1 | FORMULATION FOR PROTECTION AGAINST OXIDATIVE STRESS CONTAINING BENZOFURANONE DERIVATIVES | MERCK PATENT GmbH (DE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001055128-A1 | FORMULATION FOR PROTECTION AGAINST OXIDATIVE STRESS CONTAINING BENZOFURANONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2001-08-02 | — | — | WO | disclosed |
| EP-1109539-A1 | NANOGEL NETWORKS AND BIOLOGICAL AGENT COMPOSITION THEREOF | SUPRATEK PHARMA, INC. (CA) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000058503-A2 | IMPROVED METHOD FOR DETECTING MICRO-ORGANISMS | ZETATRONICS LIMITED (GB) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000013677-A1 | NANOGEL NETWORKS AND BIOLOGICAL AGENT COMPOSITION THEREOF | SUPRATEK PHARMA, INC. (CA) | 2000-03-16 | — | — | WO | disclosed |
| EP-0908172-A1 | Cosmetic and dermatological photoprotective compositions in the form of O/W emulsions containing hydrophobic inorganic micropigments and hydrophilic surfactants | Beiersdorf Aktiengesellschaft (DE) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170105910-A1 | UV FILTER CAPSULE | UROD, MITF, NISCH | MAPK1 4145/4885LGALS8 3846/4885LGALS3 4323/4885 |
| US-10278911-B2 | Compositions containing cyclic peptides and methods of use | CUTA, NGLY1, CALCA | MAPK1 3603/4885LGALS8 653/4885LGALS3 355/4885 |
| US-20080269163-A1 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis | GZMB, RNASE1, CASP3 | MAPK1 4514/4885LGALS8 124/4885LGALS3 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.